India’s Precision Medicine: A Vision Hindered by Biobank Regulations

Precision medicine, a transformative approach to healthcare, is redefining the landscape of disease diagnosis and treatment. From groundbreaking personalised healthcare solutions to innovations like mRNA vaccines and gene-editing technologies, the field promises a new era in medical science. Yet, as India stands on the cusp of this revolution, a significant hurdle looms: the lack of robust biobank regulations.

Organ-on-chip device Biobanks, essential repositories of biological samples, are critical to the success of precision medicine. These collections of blood, DNA, and tissue samples, coupled with genetic data, form the backbone of research aimed at developing targeted therapies for diseases like cancer and diabetes. However, as highlighted in a recent analysis by The Hindu, India’s inconsistent biobank regulations threaten public trust and impede progress.

The Promise of Precision Medicine

In recent years, precision medicine has witnessed remarkable achievements. Through gene therapy, researchers have restored vision in individuals with genetic mutations, while in the U.K., scientists have reversed diabetes using reengineered stem cells. The rapid development of COVID-19 vaccines using the mRNA platform, which earned a Nobel Prize, further underscores the potential of precision medicine.

India’s Growing Market

The Indian precision medicine market is burgeoning, with projections estimating a value exceeding $5 billion by 2030. Initiatives like the BioE3 policy and the approval of NexCAR19, a domestically developed CAR-T cell therapy, mark significant strides. However, the true potential of these advancements lies in aligning biobank regulations with international standards.

The Biobank Conundrum

Biobank While countries like the U.K., U.S., and Japan have comprehensive biobank regulations ensuring data protection and privacy, India’s framework remains fragmented. The absence of a single authority to regulate biobanks and the lack of penalties for misconduct create risks of ethical violations and undermine public confidence. As the ICMR guidelines illustrate, participants often consent to provide samples without clarity on data usage, raising concerns about privacy and potential discrimination.

A Path Forward

To harness the full potential of precision medicine, India must establish stringent biobank regulations. Aligning with global standards will not only bolster public trust but also position India as a leader in next-generation therapeutics. As part of international groups like the Quad and BRICS, India has the opportunity to expand its pharmaceutical leadership and enhance its soft diplomatic efforts.

Manjeera Gowravaram, a PhD in RNA biochemistry, provides insightful analysis on the intersection of science and policy.

More Articles

Getting licensed or staying ahead in your career can be a journey—but it doesn’t have to be overwhelming. Grab your favorite coffee or tea, take a moment to relax, and browse through our articles. Whether you’re just starting out or renewing your expertise, we’ve got tips, insights, and advice to keep you moving forward. Here’s to your success—one sip and one step at a time!

Proptech Promised a Revolution — So Why Does Real Estate Still Feel the Same?

Despite billions poured into proptech and a decade of flashy digital upgrades, the real estate experience remains largely unchanged. Apps made processes smoother, but not more transparent — because the industry’s core structures, data control and power dynamics stayed the same. True disruption will come from platforms that shift information and control to consumers, not just digitize outdated systems.

CRE Markets Wake Up in 2026: What Real Estate Professionals Need to Know

Early 2026 is delivering a clear message: commercial real estate is entering a recalibration phase. Construction is softening, pending home sales just saw a sharp drop, consumer sentiment is inching upward but remains fragile, and capital markets are tightening as major CRE sectors face rising distress. From data centers powering ahead to CMBS foreclosures climbing and office-to-residential conversions gaining momentum, professionals across real estate, mortgage, insurance, and finance need to stay sharp as the industry shifts.

Top 10 Highest-Paying Real Estate Careers of 2026

Discover the real estate roles earning the biggest paychecks in 2026. From investment consultants to commercial leasing managers, this breakdown highlights the salaries, responsibilities, and career paths offering the strongest financial potential in today’s evolving market—perfect for newcomers and seasoned professionals mapping their next big move.

Montana Launches Bold Licensing Reform Task Force to Boost Workforce Participation

Montana is taking major steps to remove outdated licensing barriers and strengthen its workforce. Governor Greg Gianforte has created a new Licensing Reform Task Force aimed at modernizing regulations, speeding up approvals, and helping more professionals enter high‑demand fields like construction and healthcare. With licensing numbers doubling over the past decade and rural communities facing critical shortages, the state is pushing for faster, more efficient pathways to work. The task force begins meeting in February and will deliver its full reform report by September 2026 — a move that could influence licensing modernization efforts nationwide.

AI Becomes Standard Gear for Real Estate Agents in 2026

Artificial intelligence has officially moved from novelty to necessity in the real estate world. According to new industry data, 97% of brokerage leaders say their agents now rely on AI tools for everything from listing descriptions to full-scale marketing campaigns. As adoption skyrockets, so do concerns over training, accuracy, and compliance — especially among smaller firms. The message is clear: for today’s real estate professionals, AI literacy isn’t optional anymore.

How the Biggest Players Shaped the 2025 Commercial Real Estate Comeback

Commercial real estate roared back to life in 2025, with more than $255B pouring into multifamily, industrial, office and retail assets. Major investors moved fast on falling interest rates, improving bond yields and rising confidence across sectors. Multifamily dominated with over $115B in deals, industrial surged under private equity leadership, office saw renewed activity from owner-users and retail proved surprisingly resilient. For today’s real estate and finance professionals, the message is clear: opportunity favors those who stay informed and ready to act.